We explored the clinical value of 18F-FDG PET/MR in a head-to-head comparison with PET/CT in loco-regional recurrent and metastatic cervical lymph nodes of differentiated thyroid carcinoma (DTC) patients after comprehensive treatment. 18F-FDG PET/CT and neck PET/MR scans that were performed in DTC patients with suspected recurrence or cervical lymph node metastasis after comprehensive treatment were retrospectively analyzed. Detection rates, diagnostic efficacy, image conspicuity, and measured parameters were compared between 18F-FDG PET/CT and PET/MR. The gold standard was histopathological diagnosis or clinical and imaging follow-up results for more than 6 months. Among the 37 patients enrolled, no suspicious signs of tumor were found in 10 patients, 24 patients had lymph node metastasis, and 3 patients had both recurrence and lymph node metastases. A total of 130 lesions were analyzed, including 3 malignant and 6 benign thyroid nodules, as well as 74 malignant and 47 benign cervical lymph nodes. Compared with PET/CT, PET/MR presented better detection rates (91.5% vs. 80.8%), image conspicuity (2.74 ± 0.60 vs. 1.9 ± 0.50, p < 0.001, especially in complex level II), and sensitivity (80.5% vs. 61.0%). SUVmax differed in benign and malignant lymph nodes in both imaging modalities (p < 0.05). For the same lesion, the SUVmax, SUVmean, and diameters measured by PET/MR and PET/CT were consistent and had significant correlation. In conclusion, compared with 18F-FDG PET/CT, PET/MR was more accurate in determining recurrent and metastatic lesions, both from a patient-based and from a lesion-based perspective. Adding local PET/MR after whole-body PET/CT may be recommended to provide more precise diagnostic information and scope of surgical resection without additional ionizing radiation. Further scaling-up prospective studies and economic benefit analysis are expected.
1 December 2025 in Quantitative Imaging in Medicine and Surgery
Background: Neoadjuvant chemotherapy (NACT) is an important part of comprehensive breast cancer treatment. However, considering that not all patients respond well, how to identify responders as soon as possible is a significant issue. Magnetic resonance imaging (MRI) shows excellent diagnostic accuracy in breast cancer, while whether it is able to identify NACT responders is not clear. In this study, we aim to evaluate the role of early percentage apparent diffusion coefficient change (ΔADC%) in predicting response to NACT in patients with breast cancer. Methods: We searched studies in PubMed, Web of Science, and Cochrane Library up to April 28, 2025. The inclusion criteria were: predicting response to NACT in breast cancer; using ΔADC% as prediction parameter; diffusion-weighted imaging (DWI)-MRI images were acquired before NACT beginning and early during NACT (after 1 or 2 cycles); providing exact criteria for responders. The exclusion criteria were: not in English or Chinese; animal studies; review/meta-analysis/abstract/case report; the number of true-positive (TP), false-negative (FN), false-positive (FP), and true-negative (TN) findings cannot be extracted directly or indirectly. The methodological quality of the included studies was assessed by Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2. Sensitivity, specificity, and summary receiver operating characteristic (SROC) curve were used to evaluate the prediction accuracy. Sub-group analyses were used to find the source of heterogeneity. For the retrospective study, 47 patients with breast cancer from our hospital were included. We used the Mann-Whitney U test to compare the ΔADC% between the pathological complete response (pCR) and non-pCR group. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to evaluate the prediction ability. Results: In the meta-analysis, 11 studies and 681 patients were included. Pooled sensitivity and specificity were 0.71 [95% confidence interval (CI): 0.60–0.79] and 0.78 (95% CI: 0.68–0.85), respectively. AUC was 0.81 (95% CI: 0.77–0.84). There was no obvious difference between the sub-groups. In the validation study, ΔADC% was significantly higher in the pCR group than in the non-pCR group. When 20.3% was chosen as the cut-off value, ΔADC% had a sensitivity of 64.7% and a specificity of 73.3% in predicting pCR. Conclusions: ΔADC% may be valuable in early prediction of response to NACT in breast cancer. The results need further validation in a larger population.
Beyond established risk factors such as genetics and hormones, the human microbiome has emerged as a pivotal player in breast cancer pathogenesis. This review delineates the technological evolution in breast microbiome research, spanning traditional culture methods to high-throughput sequencing and cutting-edge spatial omics. We elucidate the role of the gut-breast axis in modulating breast cancer development through its influence on estrogen metabolism, immune responses, and microbial metabolites. Furthermore, we analyze the distinctive compositional features of the intratumoral microbiota and their dual, context-dependent roles in promoting invasion, inducing immunosuppression, and driving metabolic reprogramming within the tumor microenvironment. Novel microbiome-based therapeutic strategies, including targeted microbiota depletion, engineered microbial therapeutics, and dietary interventions, are summarized. Finally, we discuss the translational potential of microbiome research in refining breast cancer risk prediction, evaluating treatment responses, and advancing personalized prevention and treatment strategies, ultimately contributing to improved patient outcomes.
Metabolic reprogramming constitutes a fundamental hallmark of malignancy, orchestrating a hostile tumor microenvironment (TME) that severely compromises anti-tumor immunity. Despite the transformative success of immune checkpoint blockade and adoptive cell therapies, clinical efficacy is frequently curtailed by the metabolic barriers imposed by the TME. This review systematically elucidates the complex metabolic interplay between tumor cells and infiltrating T cells, highlighting two defining mechanisms driving immune evasion: the competitive sequestration of essential nutrients and the accumulation of immunosuppressive oncometabolites. We detail how the depletion of glucose and critical amino acids (glutamine, arginine, methionine, etc.) imposes a state of “metabolic siege” on T cells, impairing their bioenergetics and effector functions. Concurrently, we explore how accumulated metabolites—such as lactate, succinate, 2-hydroxyglutarate, kynurenine, and lipids—function as non-canonical signaling molecules to subvert immune surveillance via epigenetic remodeling and oxidative stress. Furthermore, we synthesize emerging therapeutic strategies designed to dismantle this metabolic barrier, including targeting metabolic enzymes (IDO1 and FASN) and transporters, repurposing metabolic waste, and genetically engineering T cells with enhanced metabolic fitness and resilience. By integrating the latest insights into the “metabolism–epigenetics–immunity” axis, this review provides a theoretical foundation for developing next-generation immunotherapies that target metabolic vulnerabilities to overcome resistance in cancer treatment.
Reoperation for papillary thyroid carcinoma (PTC) requires precise lymph node metastasis assessment, yet ultrasound (US) alone may be insufficient in complex or high-risk cases. This study evaluated whether supplementing US with magnetic resonance imaging (MRI) improves surgical guidance and outcomes in reoperation. We retrospectively analyzed 375 patients who underwent reoperation between 2014 and 2022. Propensity score matching yielded 101 patients in the USUS-only group and 62 in the US+MRI group. Pathological and imaging data were compared to assess diagnostic performance, surgical outcomes, biochemical responses, and recurrence-free survival. The combined approach significantly increased sensitivity for detecting central lymph node metastasis from 52.5% to 90.9% and resulted in higher rates of central neck dissections (65.1% versus 45.5%) with greater lymph node yield (median: 29 versus 20) but lower lymph node ratios. More patients in the combined group achieved excellent biochemical responses (50.0% versus 27.7%). While overall recurrence-free survival (RFS) was not significantly different, the US+MRI group showed improved RFS among patients with ≥2 positive central nodes (HR = 0.24, p = 0.032). Importantly, complication rates were comparable, suggesting that improved outcomes were achieved without added surgical risk. Combined US and MRI assessment enhances diagnostic performance and may improve surgical and oncological outcomes in select high-risk patients undergoing PTC reoperation.
Autoimmune thyroiditis (AIT) is characterized by extensive lymphocytic infiltration and progressive destruction of thyroid follicular cells (TFCs), yet the molecular mechanisms underlying persistent thyroid injury remain poorly defined. Here, methyltransferase‐like 3 (METTL3) mediated N 6 ‐methyladenosine (m 6 A) modification is identified as a central driver of thyroid inflammation. METTL3 expression and m 6 A levels were markedly increased in TFCs from AIT patients and EAT mice, and are positively associated with immune inflammation scores. Genetic or pharmacological inhibition of METTL3 suppressed the KDR (kinase insert domain receptor, also known as vascular endothelial growth factor receptor 2, VEGFR2)/VEGFA signaling loop, reduced inflammatory cytokine release and lymphocyte infiltration, restored Th17/Treg homeostasis, and alleviated thyroid injury. Mechanistically, ROS promoted METTL3 transcription through inhibition of SIRT1‐dependent epigenetic repression, while METTL3‐mediated m6A modification stabilized KDR mRNA in a YTHDC2‐dependent manner. In turn, activated KDR established an autocrine‐paracrine KDR/VEGFA amplification circuit that sustained inflammatory signaling. Together, these findings uncover the METTL3‐KDR axis as a critical epitranscriptomic mechanism driving chronic thyroid inflammation and nominate it as a promising therapeutic target for AIT.